Process for preparation of high-purity meloxicam and meloxicam potassium salt

a technology of meloxicam and potassium salt, which is applied in the field of preparation of high-purity meloxicam and meloxicam potassium salt, can solve the problems of toxic and costly solvents, halogenated organic solvents that require extensive analytical testing, and harmful to the environment, and achieves high purity

Inactive Publication Date: 2012-02-09
MEZEI TIBOR +12
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This method allows for the production of meloxicam in high purity, effectively removing impurities and reducing production costs while avoiding environmental hazards, with a significant reduction in thermal decomposition and the use of non-toxic solvents.

Problems solved by technology

The above mentioned process has the disadvantage that toxic and costly solvents are used, which are harmful to the environment as well.
Use of halogenated organic solvents requires extensive analytical testing, because the residual solvent concentration must be determined in costly analytical measurements.
Due to its low yield and high production costs, this process is not used on an industrial scale.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for preparation of high-purity meloxicam and meloxicam potassium salt
  • Process for preparation of high-purity meloxicam and meloxicam potassium salt
  • Process for preparation of high-purity meloxicam and meloxicam potassium salt

Examples

Experimental program
Comparison scheme
Effect test

example 1

4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide potassium salt monohydrate (compound of the Formula I)

[0055]350 ml of xylene are transferred into an apparatus equipped with Marcusson head and provided with means for inert gas purging. Purging with argon is started and 35.0 g (130 mmol) 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid methylester of the Formula (III) [wherein the meaning of R is methyl], 15.0 g (132 mmol) of 2-amino-5-methyl-thiazole of the Formula (IV) and 6.0 g of activated carbon are added during continous stirring and argon purge.

[0056]The reaction mixture is heated for 24 hours using an oil bath at a temperature between 170 and 180° C. The heating is adjusted in a way that only a minimal amount of distillate (2-5 ml / hour) is produced in the head. Distillation of methanol is ceased by the end of the reaction.

[0057]The reaction mixture is cooled to 25° C., crude meloxicam containing carbon and approximately 12% o...

example 2

4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (compound of Formula (II), polymorph I form of meloxicam

[0065]34.1 g (83.7 mmol) meloxicam potassium salt monohydrate are dissolved in the mixture of 1500 ml of 0.5% aqueous potassium hydroxide solution and 25 ml of ethanol at the temperature of 40-45° C. by stirring for 30 minutes. The yellow solution are added 2.0 g of activated carbon and after stirring for ten minutes, the carbon is filtered off. The filtrate are added 100 ml aqueous hydrochloric acid solution prepared by diluting 20 ml (23.6 g) concentrated hydrochloric acid to 100 ml final volume, at 30° C. in 30 minutes (pH 3-5). The suspension is stirred for two hours at 10° C. temperature, filtered and the product is washed on the filter with water.

[0066]Yield: 28.5 g (97.1% calculated on the basis of the weight of meloxicam potassium salt monohydrate as starting compound)

[0067]Melting point: 246-248° C.

[0068]Elemental analysis (C14H1...

example 3

4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide potassium salt monohydrate (compound of the Formula (I))

[0070]One proceeds according to Example 1 with the difference that instead of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid methylester [compound of the Formula (III), wherein R is methyl)], 36.83 g (130 mmol) 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid ethylester [compound of the Formula (III), wherein R is ethyl] are used.

[0071]Yield: 46.9 g (88.5% calculated on the basis of the weight of the starting compound -hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid methylester of the Formula (III)).

[0072]Content (on the basis of potassium content): 99.6%

[0073]Water (Karl Fischer method): 4.7%

[0074]Elemental analysis [C14H12KN3O4S2.H2O (407,5)]

CalculatedC: 41.26H: 3.46N: 10.31S: 15.74MeasuredC: 41.22H: 3.38N: 10.25S: 15.69

[0075]Purity (HPLC): 99.8%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a process for the preparation of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide of the Formula (II),also known by the International Nonproprietary Name (INN) meloxicam and its potassium salt monohydrate of the Formula (I)in high purity.TECHNICAL BACKGROUND OF THE INVENTION[0002]Meloxicam belongs to the group of non-steroidal antiinflammatory drugs. It exerts its pharmacological effect by the inhibition of the cyclooxygenase (COX) enzyme system, which has significant role in the development of inflammatory processes. The medicinal importance of meloxicam resides in the fact that meloxicam selectively inhibits the COX-2 enzyme. This phenomenon results in less adverse effects during the medication period. It was found that the probability of the development of kidney-related or gastrointestinal adverse effects is significantly lower during the treatment using meloxicam than in those...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/5415A61P29/00C07D279/16
CPCC07D417/12A61P27/00A61P29/00A61P43/00
InventorMEZEI, TIBORSIMIG, GYULAMOLNAR, ENIKOLUKACS, GYULAPORCS-MAKKAY, MARTAVOLK, BALAZSHOFMANNE FEKETE, VALERIANAGY, KALMANMESTERHAZY, NORBERTKRASZNAI, GYORGYDONATH, GYORGYI VERECZKEYNEKORTVELYESSY, GYULANEPECSI, EVA
OwnerMEZEI TIBOR